|
|
Funding Friday 04/23/2021 Edition 27
----- Division of Research -----
|
|
Please forward and share with other faculty who may be interested. |
|
Emergency Award: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01 Clinical Trials Optional) RFA-OD-21-009. Up to $400,000 per year for a maximum of 2 years. NIH intends to commit $24 Million over 2 years to fund approximately 16 awards. Applications Due: 07/07/2021.
High rates and disparities of COVID-19 infection, morbidity, and mortality continue among underserved and vulnerable populations across the United States. The overarching goal of the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative is to understand and ameliorate factors that have placed a disproportionate burden of the pandemic on underserved and/or vulnerable populations, specifically by implementing programs that expand the scope and reach of COVID-19 testing interventions to reduce these disparities. To address barriers to testing and vaccination, social, ethical, and behavioral research is urgently needed to inform related mitigation efforts. This Phase II RADx-UP Funding Opportunity Announcement (FOA) is designed to expand research to understand and address the social, ethical, and behavioral implications (SEBI) of COVID-19 testing interventions among underserved and vulnerable populations. Desirable studies for Phase II will move beyond descriptive health disparities research to focus on developing interventions and other actionable solutions in collaboration with community partners and stakeholders. The funding for this initiative is provided from the American Rescue Plan Act of 2021.
|
|
Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations - RADx-UP Phase II (U01 Clinical Trial Optional) RFA-OD-21-008. Up to $750,000 per year for a maximum of 2 years. NIH OD intends to commit $100,000,000 in FY2022 to fund 25-50 awards. Applications Due: 07/07/2021.
This funding opportunity announcement (FOA) uses an emergency U01 mechanism to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines. The funding for this initiative is provided from the American Rescue Plan Act of 2021 .
|
|
The Office of Sponsored Programs will be the submitting authorized official for these announcements. We strongly encourage Principal Investigators to utilize the UNLV Corporate & Foundation Relations assistance with the preparation of any narrative portions of the proposal(s).
|
|
William T. Grant Foundation Invites Applications for Research Grants on Reducing Inequality. Up to $600,000 over three years. To support research that aims to build, test, or increase understanding of programs, policies, or practices that can reduce inequality in the academic, social, behavioral, or economic outcomes of young people. Letters of Inquiry due May 5, 2021. Learn more about the William T. Grant Foundation Opp
|
|
Crohn’s & Colitis Foundation Invites LOIs for Research. Up to $115,830 per year for up to three years. To support its Senior Research Awards program, which provides established researchers with funds needed to generate sufficient preliminary data to become competitive for funds from other sources. Letters of Intent due May 5, 2021. Learn more about the Crohn's & Colitis Foundation Opp
|
|
Request for Proposals (RFP) Enzalutamide in the Treatment of Prostate Cancer. The overall aim of this RFP is to develop innovative, novel, and impactful studies that address unmet needs as well as support the design and performance of enzalutamide research in the treatment of prostate cancer. Clinical trials, prospective studies, and retrospective correlative studies of enzalutamide treatment trials or datasets are encouraged. It is hoped proposals submitted in response to this RFP will guide development of enzalutamide and its combination with other therapies. Application Due Date: 05/14/2021. Learn more about this Enzalutamide Opp
|
|
Request for Proposals (RFP) Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Nurse Navigator Competitive Grant Program. Projects that will be considered for funding will focus on supporting the development of nurse navigator programs, including training, in order to improve the quality of care for ATTR-CM patients. Application Due Date: 06/15/2021. Learn more about this ATTR-CM Opp
|
|
Request for Proposals (RFP) Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research - U.S. Projects that will be considered for Pfizer support will focus on several or one specified area: 1) Early identification, evaluation, diagnosis, prognosis & treatment; 2) Study of hereditary ATTR genotypes and phenotypes (Non-Val30Met genotypes; Val122Ile, Thr60Ala, Val30Met, and others); 3) Mixed phenotypic manifestations (e.g. polyneuropathy and cardiomyopathy); or 4) Use of tafamidis in the clinical setting (i.e. real-world evidence). Application Due Date: 06/09/2021. Learn more about this ATTR-CM-Research Opp
|
|
Request for Proposals (RFP) Management of Metabolic Risks that Drive Liver Diseases and Increase Cardiovascular Risk in NASH. Provide independent grant(s) to an organization or organizations that will focus on the management of metabolic disorders’ risks that drive liver disease outcomes and increase cardiovascular risk in non-alcoholic steatohepatitis (NASH). Application Due Date: 06/15/2021. Learn more about this RFP Opp
|
|
Althea Sheets, Communications Manager, Office of Sponsored Programs, [email protected], 702-895-1880
|
|
|
|
|
|
|
|
